Champions Oncology, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2012, compared with fiscal 2011. Although the request identifies “2011 Q4,” this filing is an annual report for fiscal 2012, not a standalone quarterly report. Filed July 18, 2012.
Business context
Champions develops oncology services using its TumorGraft platform, which implants human tumors in immune-deficient mice. Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. The company shifted its strategy toward its core platform, reduced POS prices to expand access and tumor-model supply, and moved laboratory work from a third-party CRO to its Baltimore facility during the second half of fiscal 2012.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $7.149 million | $6.882 million |
| POS revenue | $2.332 million | $3.382 million |
| TOS revenue | $4.817 million | $3.500 million |
| Operating loss | $9.065 million | $5.235 million |
| Net loss | $8.661 million | $3.802 million |
| Net loss per share | $0.19 | $0.11 |
| Cash used in operations | $5.227 million | $0.054 million |
| Cash and cash equivalents at year-end | $4.754 million | $10.457 million |
- Revenue grew 3.9% overall: TOS rose 37.6%, while POS fell 31.0%. POS panel revenue declined with lower pricing; excluding panels, POS revenue increased modestly. TumorGraft implants rose to 97 from 12, and completed drug studies to 19 from 5.
- Total costs and operating expenses increased 33.8% to $16.214 million. Sales and marketing expense rose 169.9% to $2.928 million, reflecting expansion of sales and marketing; general and administrative expense rose 18.2% to $5.450 million.
- POS gross margin fell to negative 1% from 51%, reflecting price reductions, transition costs from bringing laboratory work in-house, and costs of ongoing studies. TOS gross margin was 47% in both years.
- Working capital was $2.1 million. Current assets were $5.543 million and current liabilities $3.486 million; cash included $150,000 of restricted cash reported as noncurrent. Management stated cash on hand was adequate to fund operations for at least the next 12 months.
- The company reported no off-balance-sheet debt or similar obligations. The filing shows a $555,000 warrant liability, but no conventional borrowings are reported on the balance sheet.
Changes, outlook, and material risks
- The net loss more than doubled, and operating cash use increased substantially year over year. Revenue growth did not keep pace with rising costs.
- Other income declined to $402,000 from $1.444 million. FY 2011 included approximately $1.5 million of federal therapeutic-discovery grant income; FY 2012 included $417,000 of income from a decrease in the estimated fair value of warrant liabilities.
- Management expects ongoing operating losses until revenue grows sufficiently to cover expenses. No quantified revenue, earnings, or cash-flow guidance is provided. Management anticipated future cost savings from in-house laboratory operations and was evaluating options to expand lab capacity.
- The company said additional capital may be required if cash needs exceed available resources; future financing could be unavailable, costly, restrictive, or dilutive. POS prices and margins, customer growth, and the expected savings from the laboratory transition are important execution uncertainties.
- About 12.533 million shares issued in the 2011 private placement are classified as redeemable common stock because investors have a conditional cash put right upon a change of control or sale of substantially all assets. The placement also included warrants with exercise-price reset provisions. Outstanding options and warrants create potential dilution.
- The TumorGraft platform is proprietary but not patented. Other key risks include competition from larger companies, reliance on key scientific staff, regulatory uncertainty, dependence on a single Baltimore laboratory, and the thin, volatile OTC market for the shares.
- The Cephalon agreement offers potential milestone payments totaling $27 million, contingent on compound performance, clinical testing, and FDA approval; no milestones had been achieved and no royalties earned by year-end. Champions was evaluating strategic options, including a partner, to finance further development of Irinophore C.
- The IRS examination resulted in a $607,000 reduction to net operating loss carryforwards, offset by an increase in amortizable intangible assets related to capitalized research and development. The separate examination of the therapeutic-discovery grant program resulted in no additional tax due or receivable.
- The independent auditor issued an unqualified opinion on the financial statements. Management reported disclosure controls and internal control over financial reporting were effective; the auditor did not express an opinion on internal control effectiveness.
Most important facts for investors to verify
- Whether management’s stated minimum 12-month cash runway remained supportable given the $5.227 million annual operating cash outflow and year-end cash balance.
- Whether in-house laboratory operations deliver the expected cost savings and support higher study volumes without harming service quality or margins.
- Whether TOS growth and POS volume can produce sustainable revenue and improved gross margins after strategic price reductions.
- The status and terms of any future financing, including the potential effects of redeemable shares, warrant resets, options, and other dilution.
- Progress under the Cephalon agreement, including completion of studies and any milestone or royalty eligibility, and the funding plan for Irinophore C.